AIVIS (CEO Daehong Lee), an AI-driven digital pathology solutions company, announced on December 23 that it has won the Excellence Award at the 2025 K-Digital Grand Championship, hosted by the Ministry of Science and ICT (MSIT) and organized by the National IT Industry Promotion Agency (NIPA). The K-Digital Grand Championship is a government-led competition designed to identify and promote companies with innovative AI- and data-driven technologies. Following a rigorous preliminary screening, seven teams advanced to the final round this year. Notably, AIVIS was the only company representing the medical AI sector, drawing significant attention. With the award, AIVIS received KRW 20 million in prize money, along with opportunities to link to future government-funded programs and potential investment support. At the final presentation, AIVIS highlighted clinical outcomes and real-world applications of its flagship solution, Qanti® IHC, demonstrating how the technology improves the accuracy and consistency of cancer diagnostics. The presentation received strong evaluations from the judging panel. Pathology, widely regarded as the gold standard for cancer diagnosis, requires extensive expertise. Yet increasing biomarker complexity and inter-observer variability among pathologists remain long-standing challenges. Qanti® IHC addresses these issues by reducing subjective interpretation and enabling precise, AI-based quantitative biomarker analysis. The solution secured regulatory approval from Korea’s Ministry of Food and Drug Safety (MFDS) in September 2024. Within approximately one year of its launch, it has been adopted by 12 major tertiary hospitals in Korea, demonstrating rapid market traction. Hospitals using Qanti® IHC can also support reimbursement justification under pathology morphometric analysis fees, making the solution attractive not only for its clinical value but also from an operational and economic perspective. AIVIS’s technology has also been validated internationally. From December 5 to 7, the company presented results from a joint clinical study conducted with the Breast Pathology Study Group of the Korean Society of Pathologists at ESMO Asia 2025 in Singapore. The study assessed the performance of the Qanti® Breast HER2 AI solution as a diagnostic aid for HER2 (Human Epidermal Growth Factor Receptor 2) assessment in 168 breast cancer patients from Samsung Medical Center. The results showed that Fleiss’ kappa, a measure of inter-pathologist agreement, increased from 0.5181 without AI assistance to 0.7232 with AI support—an improvement from “moderate” to “substantial” agreement. The study also reported statistically significant improvements in diagnostic accuracy across all HER2 expression categories. Building on these milestones, AIVIS is accelerating its global expansion. The company is currently collaborating with AstraZeneca Korea on a project aimed at improving the diagnostic environment for HER2-low breast cancer. In parallel, AIVIS has established partnerships with leading global pathology equipment companies, including Philips, Roche, and Leica. AIVIS is also conducting global proof-of-concept (PoC) projects with more than 20 major hospitals across Asia, actively exploring international commercialization opportunities for Korean-developed pathology AI technologies. CEO Daehong Lee stated, “This award recognizes more than technological innovation—it demonstrates that pathology AI is delivering tangible value in clinical practice and across the healthcare industry. By providing accurate and consistent diagnostic technologies, we aim to enhance the quality of cancer treatment and grow into a platform company that leads global standards in cancer diagnostics.”